SCHEMBL4177487

SCHEMBL4177487

CCc1cc(S(=O)(=O)N2CCCN(S(=O)(=O)c3ccc(OC)c(OC)c3)CC2)ccc1OC

nearest known ligand 0.82

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 1/20 0.82
LMNA P02545 3/20 0.65
MAPT P10636 1/20 0.62
TSHR P16473 5/20 0.58
HSD17B10 Q99714 2/20 0.58
USP2 O75604 1/20 0.58
GLA P06280 1/20 0.58
MAPK1 P28482 1/20 0.58
MCOLN3 Q8TDD5 2/20 0.58
HTT P42858 2/20 0.57
POLB P06746 1/20 0.57
PKM P14618 1/20 0.57
ALDH1A1 P00352 3/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
KDM4E B2RXH2 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4179437 0.96 GPBAR1 (0.74) GPBAR1LMNAMAPTTSHRHSD17B10
Sb-756050 SCHEMBL4174350 0.90 GPBAR1 (1.00) GPBAR1LMNAMAPTTSHRHSD17B10
SCHEMBL6367892 0.89 GPBAR1 (0.97) GPBAR1LMNAMAPTTSHRHSD17B10
SCHEMBL7209087 0.86 GPBAR1 (0.91) GPBAR1LMNATSHRHSD17B10USP2
SCHEMBL3830421 0.86 GPBAR1 (0.90) GPBAR1LMNAMAPTTSHRHSD17B10
SCHEMBL4184681 0.86 GPBAR1 (0.90) GPBAR1LMNAMAPTTSHRHSD17B10
SCHEMBL7205052 0.84 GPBAR1 (0.88) GPBAR1LMNATSHRHSD17B10USP2
SCHEMBL4193765 0.83 GPBAR1 (0.84) GPBAR1LMNAMAPTTSHRHSD17B10
SCHEMBL4181812 0.81 GPBAR1 (0.80) GPBAR1LMNAMAPTTSHRHSD17B10
SCHEMBL4186414 0.81 GPBAR1 (0.52) GPBAR1LMNAMAPTTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US claimed
EP-1976498-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2008-10-08 EP claimed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 WO claimed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
EP-1976498-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2008-10-08 EP disclosed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 WO disclosed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069302-A1 CHEMICAL COMPOUNDS TBXA2R, PDE4D, PDE4A GPBAR1 81/4885LMNA 3674/4885MAPT 1286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.